Results 161 to 170 of about 926 (182)
Some of the next articles are maybe not open access.
Saroglitazar, a dual PPAR-α/γ agonist, alleviates LPS-induced hepatic and renal injury in rats
International Immunopharmacology, 2023Ahmed R El-Sheakh +2 more
exaly
Histologische Effekte von Saroglitazar bei NASH untersucht
Zeitschrift für Gastroenterologie, 2022openaire +1 more source
Saroglitazar for Nonalcoholic Fatty Liver Disease: A Single Centre Experience in 91 Patients
Journal of Clinical and Experimental Hepatology, 2022Prateek Padole, Praveen Sharma
exaly
Saroglitazar as a Treatment Modality for Dyslipidemic Transaminitis in Nafld Patients
Journal of Clinical and Experimental Hepatology, 2022openaire +1 more source
Saroglitazar Reduces Predictor Lipid Biomarkers Of Cardiovascular Diseases
Atherosclerosis, 2019M. Krishnappa +5 more
openaire +1 more source
Saroglitazar - A novel treatment for non-alcoholic steatohepatitis
AIP Conference ProceedingsShifa Noorani +8 more
openaire +1 more source
Abstract #1311: Saroglitazar in Non-Alcoholic Fatty Liver Disease
Endocrine Practice, 2016Shashank Joshi +4 more
openaire +1 more source

